<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30071">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860417</url>
  </required_header>
  <id_info>
    <org_study_id>TerCel005</org_study_id>
    <secondary_id>2012-004444-30</secondary_id>
    <secondary_id>Disc_allo_MSV</secondary_id>
    <nct_id>NCT01860417</nct_id>
  </id_info>
  <brief_title>Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)</brief_title>
  <acronym>Disc_allo</acronym>
  <official_title>Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Citospin, S.L., Valladolid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scientific Park Foundation of Valladolid University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Biologia y Genetica Molecular (IBGM) de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we want to evaluate the clinical use of allogenic mesenchymal stem cells
      (MSC), obtained from bone marrow of healthy donors, for treatment of Degenerative Disc
      Disease (DDD). The trial is based in previous results with autologous MSC (Orozco et al.,
      Transplantation  92: 822-828; 2011). Here we propose a phase I-II trial, prospective,
      randomized, blinded, and controlled for the treatment DDD using MSV, a Good Manufacturing
      Practice (GMP)-compliant expanded bone marrow MSC  (MSV, PEI Num. 10-134). The assay
      consists of two arms with 12 patients each one. Patients in the experimental arm will be
      given a single intra-discal transplantation of MSV (25 millions in 2 ml). Control patients
      will be infiltrated in the paravertebral muscles close to the lesion with 2 ml of 1%
      mepivacain. We shall follow the evolution of pain, disability and quality of life as well as
      disc fluid content by Magnetic Resonance Imaging (T2-calibrated).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events will be used as a measure of safety and tolerability. Adverse events reported: clinical review and questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain, disability and life quality evolution (Visual Analogue Scales (VAS) and Oswestry questionnaire and Short Form (SF)-12 scores)</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical review, questionaires for pain, disability and quality of life at 0, 3, 6 and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)</measure>
    <time_frame>up to one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>RMI density measurements in T2 weighted images performed at 0, 6 and 12 months used as an indication of disc fluid content</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Intervertebral Disc Disease</condition>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Allogenic Mesenchymal Stromal Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic Mesenchymal Stromal Cells</intervention_name>
    <arm_group_label>Allogenic Mesenchymal Stromal Cells</arm_group_label>
    <other_name>Mesenchymal stem cells (MSC)</other_name>
    <other_name>MSC injection</other_name>
    <other_name>MSV (MSV=MSC prepared following Valladolid IBGM procedure)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepivacaine</intervention_name>
    <arm_group_label>Mepivacaine</arm_group_label>
    <other_name>Sham-treated comparator</other_name>
    <other_name>Mepivacaine is also known as Carbocaine</other_name>
    <other_name>Mepivacaine is also known as Polocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Degenerative disease of one or two lumbar discs with predominant back pain after
             conservative treatment (physical and medical) for over 6 months.

          -  Fibrous ring capable of holding the cell implantation, demonstrated by RMI image
             (stages 2, 3 and 4 of Adams).

          -  Decrease of disc height of more than 20% (radiographic measurement in side image).

          -  Absence of spinal infection.

          -  Haematological and biochemical analysis wit no significant alterations that
             contraindicates intervention.

          -  The patient is able to understand the nature of the study.

          -  Informed written consent of the patient.

        Exclusion Criteria:

          -  Age over 75 or under 18 or legally dependent

          -  Allergy to gentamicin, or to bovine, cattle or horse serum.

          -  Congenital or acquired diseases leading to spine deformations that may upset cell
             application.

          -  Spinal segmental instability, spinal canal stenosis, isthmus pathology and other
             conditions that may compromise the study

          -  Modic III changes on MRI images (31).

          -  Overweight with body mass index (mass in Kg/size in m2) greater than 35 (obesity
             grade II).

          -  Pregnancy or breast-feeding

          -  Neoplasia

          -  Immunosuppression

          -  Participation in another clinical trial or treatment with another investigational
             product within 30 days prior to inclusion in the study.

          -  Other conditions that may, according to medical criteria, discourage participation in
             the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Garcia-Sancho, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Scientific Park Foundation of University of Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David C Noriega, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinico Universitario, Valladolid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Sanchez, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Citospin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FRancisco Ardura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario, Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Garcia-Sancho, MD, PhD</last_name>
    <phone>0034 983 184827</phone>
    <email>jgsancho@ibgm.uva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David C Noriega, MD, PhD</last_name>
    <phone>0034 983 420000</phone>
    <phone_ext>276</phone_ext>
    <email>dcnoriega1970@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Biologia y Genetica Molecular</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana SÃ¡nchez, MD, PhD</last_name>
      <phone>0034 983 184827</phone>
      <email>asanchez@ibgm.uva.es</email>
    </contact>
    <contact_backup>
      <last_name>Javier GarcÃ­a-Sancho, MD, PhD</last_name>
      <phone>0034 983 184827</phone>
      <email>jgsancho@ibgm.uva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Ana SÃ¡nchez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier GarcÃ­a-Sancho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Garcia, MsC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David C Noriega, MD, PhD</last_name>
      <phone>0034 983 420400</phone>
      <phone_ext>276</phone_ext>
      <email>dcnoriega1970@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Ardura, MD, PhD</last_name>
      <phone>0034 983 420400</phone>
      <phone_ext>276</phone_ext>
      <email>fardura@ono.com</email>
    </contact_backup>
    <investigator>
      <last_name>David C Noriega, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Ardura, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=orozco+and+garcia-sancho</url>
    <description>Treatment of Degenerative Disc Disease with Autologous Mesenchymal Stem Cells</description>
  </link>
  <link>
    <url>http://www.red-tercel.com</url>
    <description>Spanish Cell Therapy Network</description>
  </link>
  <link>
    <url>http://www.citospin.com</url>
    <description>Citospin S.L. (MSV Cell Production)</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh/?term=intervertebral</url>
    <description>Intervertebral disk</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/mesh?term=cell%2C%20mesenchymal%20stem</url>
    <description>mesenchymal stem cells</description>
  </link>
  <reference>
    <citation>Orozco L, Soler R, Morera C, Alberca M, SÃ¡nchez A, GarcÃ­a-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation. 2011 Oct 15;92(7):822-8. doi: 10.1097/TP.0b013e3182298a15.</citation>
    <PMID>21792091</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 18, 2013</lastchanged_date>
  <firstreceived_date>May 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Degenerative Disc Disease,</keyword>
  <keyword>Intervertebral Disc Disease</keyword>
  <keyword>Low Back Pain</keyword>
  <keyword>Nucleus pulposus</keyword>
  <keyword>Stem cell</keyword>
  <keyword>Cellular therapy</keyword>
  <keyword>Regenerative therapy</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Mesenchymal Stromal Cells (allogenic)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Intervertebral Disk Displacement</mesh_term>
    <mesh_term>Intervertebral Disk Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mepivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
